Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBIT (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of EBIT data on record, last reported at -$133.7 million in Q4 2025.

  • For Q4 2025, EBIT fell 41.08% year-over-year to -$133.7 million; the TTM value through Dec 2025 reached -$516.8 million, down 52.5%, while the annual FY2025 figure was -$516.8 million, 52.5% down from the prior year.
  • EBIT reached -$133.7 million in Q4 2025 per CRNX's latest filing, up from -$142.6 million in the prior quarter.
  • Across five years, EBIT topped out at -$22.9 million in Q1 2021 and bottomed at -$142.6 million in Q3 2025.
  • Average EBIT over 5 years is -$67.7 million, with a median of -$56.0 million recorded in 2023.
  • Peak YoY movement for EBIT: tumbled 64.99% in 2022, then fell 23.12% in 2023.
  • A 5-year view of EBIT shows it stood at -$30.9 million in 2021, then tumbled by 53.96% to -$47.6 million in 2022, then crashed by 31.76% to -$62.7 million in 2023, then crashed by 51.21% to -$94.7 million in 2024, then tumbled by 41.08% to -$133.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$133.7 million in Q4 2025, -$142.6 million in Q3 2025, and -$129.1 million in Q2 2025.